New data associates the application of RFA in the bile duct in conjunction with stenting to patient survival.  The study, published online by researchers from Cornell in the July issue of Digestive Diseases and Science, analyzed data collected prospectively on all patients admitted for biliary obstruction from pancreatic cancer or cholangiocarcinoma over a 3 year period.  Of the 66 patients included, 39% had RFA and stent whereas the remaining control group had stent only (the current standard of care).  Both groups were comparable for demographics, diagnosis and number of ERCPs performed.  No significant difference in the ratio of adverse events was observed.  A multivariable Cox proportional hazard statistical analysis determined the receipt of RFA to be one of the predictors of survival. 

To read the paper, click here.

Posted
AuthorFrancois Poulin